Introduction: Why STI Prevention Matters More Than Ever
In the landscape of modern public health, few topics demand as much attention, nuance, and compassionate education as the prevention of sexually transmitted infections. Despite decades of research, widespread public health campaigns, and significant advances in medical science, sexually transmitted infections continue to represent one of the most persistent and consequential health challenges facing populations around the world. The World Health Organization estimates that more than one million sexually transmitted infections are acquired every single day globally, a staggering figure that underscores the ongoing urgency of prevention, education, and open conversation.
Sexually transmitted infections, commonly referred to as STIs, are infections passed from one person to another primarily through sexual contact. They include a wide spectrum of bacterial, viral, parasitic, and fungal conditions, ranging from highly treatable bacterial infections like chlamydia and gonorrhea to chronic viral conditions like HIV, herpes, and human papillomavirus. Some STIs, if left undetected and untreated, can lead to serious long-term health consequences including infertility, chronic pain, certain cancers, and, in the case of HIV without treatment, life-threatening immune suppression.
What makes the subject of STI prevention particularly compelling from a health and wellness perspective is that the vast majority of these infections are preventable. Unlike many other health conditions where prevention is complicated by genetic predisposition, environmental factors, or limited medical tools, STIs can be dramatically reduced through a combination of knowledge, behavioral choices, consistent use of barrier methods, vaccination, regular testing, and open communication with sexual partners. The tools for prevention exist; what often stands in the way is stigma, misinformation, inadequate education, and lack of access to healthcare.
This comprehensive guide is designed to serve as a thorough, evidence-based resource on STI prevention across the full spectrum of relevant topics. We will explore the landscape of sexually transmitted infections in detail, examining the most common and significant conditions, their transmission routes, and their health consequences. We will then move into the heart of prevention, covering every major strategy available to individuals and communities. We will address the critical role of regular testing and early detection, the transformative power of vaccines, the importance of honest communication between partners, and the structural factors that shape STI risk at the population level.
Throughout this guide, the goal is not to create fear or shame, but to empower. Understanding sexual health is a fundamental component of overall wellness. Approaching sexual health with the same intentionality, informed decision-making, and proactive care that we bring to physical fitness, nutrition, or mental health is not only reasonable — it is essential for a life of genuine wellbeing.
Chapter One: Understanding the Landscape — What Are STIs and Why Do They Persist?
Defining Sexually Transmitted Infections
Sexually transmitted infections are caused by a diverse range of pathogens that share one common characteristic: they are efficiently transmitted through the exchange of bodily fluids or skin-to-skin contact during sexual activity. The term "sexually transmitted infection" is now generally preferred over the older "sexually transmitted disease" or "STD" because many infections can be present in a person's body without producing noticeable symptoms. A person can have an STI — and can transmit it to others — without ever experiencing what would classically be called a disease. This semantic distinction matters enormously for prevention, because it highlights the importance of testing even when one feels perfectly healthy.
STIs can be categorized by their causative agents into several groups. Bacterial STIs include chlamydia, gonorrhea, and syphilis, all of which are curable with antibiotics when detected. Viral STIs include HIV, herpes simplex virus types 1 and 2, human papillomavirus, and hepatitis B and C. Viral infections generally cannot be cured but can be managed effectively with antiviral medications. Parasitic STIs include trichomoniasis, caused by a single-celled parasite, and ectoparasitic infections like pubic lice and scabies, which are caused by external parasites that live on the skin.
The Global Burden of STIs
The scale of the global STI burden is almost difficult to comprehend. According to data from the World Health Organization and the Centers for Disease Control and Prevention, more than 374 million new infections with one of four curable STIs — chlamydia, gonorrhea, syphilis, and trichomoniasis — occur each year worldwide. Human papillomavirus, the most common viral STI, infects an estimated 290 million women alone globally. Approximately 38 million people are currently living with HIV. Herpes simplex virus type 2, the primary cause of genital herpes, affects an estimated 491 million people globally between the ages of 15 and 49.
In the United States alone, the CDC estimates that there are approximately 26 million new STI cases each year, contributing to a total burden of more than 68 million active STI infections at any given time. The annual economic burden of STIs in the United States is estimated in the billions of dollars when accounting for testing, treatment, and the long-term health consequences of untreated or undertreated infections.
Despite the availability of effective prevention tools and treatments, STI rates in many countries have actually been rising in recent years. Gonorrhea and syphilis rates, in particular, have seen alarming increases in multiple countries over the past decade. Several factors contribute to this persistence: inadequate sex education, persistent social stigma that prevents people from seeking testing and treatment, increasing rates of antibiotic resistance in certain bacterial STIs, reduced condom use in some populations, and structural barriers to healthcare access particularly affecting marginalized communities.
Who Is at Risk?
One of the most important things to understand about STI risk is that it is not limited to any particular group of people. STIs affect individuals across all ages, genders, sexual orientations, socioeconomic backgrounds, and geographic locations. The framing of STI risk as something that only affects "high-risk" or marginalized groups is not only scientifically inaccurate but also contributes to stigma and prevents many people from seeking the testing and care they need.
That said, epidemiological data does reveal that certain populations face disproportionate STI burdens due to a combination of social, structural, and behavioral factors. Young people between the ages of 15 and 24 account for half of all new STI cases in the United States despite representing only about a quarter of the sexually active population. Gay, bisexual, and other men who have sex with men have higher rates of HIV, gonorrhea, and syphilis compared to the general population. Black Americans face significantly higher rates of chlamydia, gonorrhea, and syphilis than white Americans, a disparity driven not by individual behavior but by structural racism, healthcare inequities, and concentrated poverty. Women face particular health consequences from STIs due to biological susceptibility and the risk of complications including pelvic inflammatory disease, infertility, and mother-to-child transmission during pregnancy and childbirth.
Understanding these disparities is essential for designing effective prevention programs, but it should never be used to stigmatize or stereotype individuals.
Chapter Two: The Major STIs — A Closer Look
Chlamydia
Chlamydia, caused by the bacterium Chlamydia trachomatis, is the most commonly reported STI in the United States and many other countries. It is estimated that millions of new chlamydia infections occur each year in the U.S. alone, with many cases going undetected because approximately 70 to 95 percent of women and about half of men with chlamydia have no symptoms at all.
When symptoms do occur in women, they may include unusual vaginal discharge, burning during urination, and pain in the lower abdomen or pelvis. Men may experience a discharge from the penis, burning during urination, or pain and swelling in the testicles. Chlamydia can also infect the throat and rectum, causing symptoms in those areas following oral or anal sex.
The health consequences of untreated chlamydia can be severe, particularly for women. It can spread to the uterus, fallopian tubes, and ovaries, causing pelvic inflammatory disease, which can lead to chronic pelvic pain, ectopic pregnancy, and infertility. In men, untreated chlamydia can cause epididymitis, a painful condition of the testicles that can, in rare cases, lead to infertility. Chlamydia during pregnancy increases the risk of preterm labor and can be transmitted to the newborn during delivery, potentially causing eye infections and pneumonia.
The good news is that chlamydia is readily diagnosed through urine tests or swabs and is easily treated with antibiotics, typically a single dose of azithromycin or a week-long course of doxycycline. Regular testing is the cornerstone of chlamydia prevention and management, particularly for sexually active young women and anyone with multiple partners.
Gonorrhea
Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is the second most commonly reported STI in the United States. Like chlamydia, gonorrhea often produces no symptoms, particularly in women, but when symptoms do occur they typically include a yellowish or greenish discharge from the genitals and burning during urination. Gonorrhea can also infect the throat, rectum, and eyes.
If left untreated, gonorrhea can cause pelvic inflammatory disease in women, leading to the same severe reproductive health consequences as untreated chlamydia. In men, it can cause epididymitis. Gonorrhea can also spread to the bloodstream and joints, a condition called disseminated gonococcal infection that can cause arthritis and, rarely, can be life-threatening.
A particularly alarming development in gonorrhea prevention is the emergence of antibiotic-resistant strains. Gonorrhea has progressively developed resistance to nearly every antibiotic class that has been used to treat it, including penicillin, tetracyclines, fluoroquinolones, and most recently, certain cephalosporins. The WHO has identified gonorrhea as a priority pathogen requiring urgent research and development of new treatment options. Current treatment recommendations typically involve a dual antibiotic therapy approach, and treatment failures are increasingly being reported globally.
Syphilis
Syphilis, caused by the spiral-shaped bacterium Treponema pallidum, is one of the oldest known STIs and one of the most complex in terms of its clinical course. After years of significant decline, syphilis rates have surged dramatically in recent years in the United States and many European countries, including alarming increases in congenital syphilis — syphilis transmitted from a pregnant woman to her baby.
Syphilis progresses through distinct stages if untreated. The primary stage is characterized by a painless sore called a chancre at the site of infection. Because the sore is painless and may be hidden inside the body, it is often not noticed. The secondary stage, which follows weeks later, involves a rash that can appear on the palms of the hands and soles of the feet, as well as flu-like symptoms. Without treatment, syphilis enters a latent stage where there are no symptoms but the bacterium remains in the body. The tertiary stage, which may occur years later, can affect the heart, brain, and other organs, leading to serious neurological and cardiovascular complications.
Syphilis during pregnancy can be devastating, potentially causing miscarriage, stillbirth, premature birth, and serious health problems for newborns including death. Screening for syphilis during pregnancy is one of the most important and cost-effective public health interventions available. Syphilis remains highly treatable with penicillin, which is remarkable given that it has been used for this purpose since the 1940s without significant resistance developing.
HIV and AIDS
Human Immunodeficiency Virus remains one of the most significant and well-known STIs globally. HIV attacks the immune system, specifically the CD4 cells that help coordinate immune responses, progressively weakening the body's ability to fight infections and certain cancers. Without treatment, HIV infection typically progresses over years to acquired immunodeficiency syndrome, or AIDS, the advanced stage of infection where the immune system is severely compromised.
Since the beginning of the epidemic, approximately 40 million people have died from AIDS-related illnesses globally. Today, approximately 38 million people are living with HIV, of whom two-thirds are in sub-Saharan Africa. In the United States, about 1.2 million people are living with HIV, with approximately 13 percent unaware of their status.
The transformation in HIV management over the past three decades has been one of medicine's great success stories. Antiretroviral therapy has made HIV a manageable chronic condition for people with access to treatment. People living with HIV who are on effective antiretroviral therapy and achieve an undetectable viral load in their blood can live long, healthy lives and cannot transmit the virus to sexual partners. This is the scientific basis for the Undetectable = Untransmittable, or U=U, concept, one of the most important advances in HIV prevention in recent decades.
HIV is transmitted through specific bodily fluids: blood, semen and pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk. It is not transmitted through casual contact, sharing food or drink, mosquitoes, or air. The primary routes of transmission are unprotected sexual contact, sharing needles or syringes, and mother-to-child transmission during pregnancy, childbirth, or breastfeeding.
Herpes
Herpes is caused by the herpes simplex virus, which comes in two types. Herpes simplex virus type 1, or HSV-1, primarily causes oral herpes, commonly manifesting as cold sores around the mouth, though it can also cause genital herpes through oral-to-genital contact. Herpes simplex virus type 2, or HSV-2, primarily causes genital herpes. Together, these two viruses are extraordinarily common: the WHO estimates that 3.7 billion people under age 50 have HSV-1 globally, and approximately 491 million people between 15 and 49 have HSV-2.
Many people with herpes have no symptoms or have symptoms so mild they go unrecognized. When symptoms do occur, they typically involve clusters of painful blisters or sores in the affected area that ulcerate and then crust over. These outbreaks may recur periodically throughout a person's life, though many people experience fewer and less severe outbreaks over time.
Herpes is transmitted through direct contact with herpes sores or through the skin during what is called asymptomatic shedding — periods when the virus is active on the skin surface without causing visible sores. This means that herpes can be transmitted even when an infected person has no symptoms and no visible sores, which is a major driver of its widespread prevalence.
There is currently no cure for herpes, but antiviral medications like acyclovir and valacyclovir can significantly reduce the frequency and severity of outbreaks and reduce, though not eliminate, the risk of transmission to partners.
Human Papillomavirus
Human papillomavirus is the most common sexually transmitted infection, with virtually all sexually active people acquiring at least one strain of HPV at some point in their lives if they are not vaccinated. There are more than 200 strains of HPV, of which more than 40 can infect the genital area. Most HPV infections clear on their own without treatment, but persistent infection with certain high-risk strains can cause cancers of the cervix, vagina, vulva, penis, anus, and throat. Low-risk strains can cause genital warts.
Cervical cancer, which is almost entirely caused by HPV, kills approximately 340,000 women globally each year. The development of highly effective HPV vaccines has been one of the most significant advances in STI prevention in history, offering the potential to dramatically reduce cervical cancer and other HPV-related cancers globally.
Hepatitis B and C
Hepatitis B and hepatitis C are viral infections that primarily affect the liver but can be transmitted sexually, particularly hepatitis B. Hepatitis B is efficiently transmitted through sexual contact and is approximately 50 to 100 times more infectious than HIV. It can cause acute hepatitis and, in a significant proportion of cases particularly in those infected in infancy, progresses to chronic hepatitis B, which can lead to cirrhosis and liver cancer. An effective vaccine for hepatitis B has been available since the 1980s.
Hepatitis C is less efficiently transmitted sexually than hepatitis B, but sexual transmission does occur, particularly among men who have sex with men and people living with HIV. Hepatitis C can also cause chronic liver disease, cirrhosis, and liver cancer. Historically a serious and difficult-to-treat condition, hepatitis C has been transformed by the development of direct-acting antiviral medications that can cure the infection in more than 95 percent of cases with short courses of well-tolerated treatment.
Trichomoniasis
Trichomoniasis, caused by the protozoan parasite Trichomonas vaginalis, is the most common curable STI in the United States and globally, though it receives far less attention than many other STIs. An estimated 3.7 million people in the United States have trichomoniasis at any given time, but only about 30 percent experience any symptoms. When symptoms do occur in women, they include itching, burning, redness of the genitals, and an unusual discharge that may be frothy, yellow-green, and have an unpleasant odor. Men typically experience no symptoms.
Trichomoniasis is easily treated with antibiotics, particularly a single dose of metronidazole or tinidazole. Despite being highly treatable, trich is often overlooked because it does not cause the severe long-term complications associated with other STIs and because of a lack of awareness. However, trichomoniasis does increase the risk of acquiring and transmitting other STIs including HIV, and in pregnant women it is associated with preterm birth and low birth weight.
Chapter Three: The Pillars of STI Prevention
Understanding what STIs are and how they affect health is the essential foundation, but the heart of any discussion about STI prevention lies in the practical strategies that individuals can employ to protect themselves and their partners. Prevention operates at multiple levels, from individual behavioral choices to structural public health interventions. The most effective prevention approach is one that combines multiple strategies tailored to an individual's specific circumstances, values, and risk factors.
Abstinence and Reducing the Number of Sexual Partners
From a purely biological standpoint, abstaining from all forms of sexual contact eliminates the risk of sexual transmission of STIs entirely. Abstinence from penetrative sex, combined with avoidance of other forms of sexual contact that can transmit infections, is the only method that provides 100 percent prevention against sexual transmission. However, it is important to acknowledge that abstinence is not a realistic or desirable long-term strategy for most adults, and public health approaches that rely exclusively on abstinence messaging have consistently been shown to be ineffective at the population level.
A more nuanced and practical approach focuses on reducing the number of sexual partners and, for those who are sexually active, making informed choices about the circumstances under which they engage in sexual activity. The mathematical reality of STI transmission is that the more sexual partners one has, and the higher the STI prevalence in those partners' networks, the greater the cumulative probability of exposure. This does not mean that having multiple partners is inherently irresponsible — it means that having multiple partners requires proportionally greater attention to other prevention strategies such as consistent condom use and regular testing.
Mutual monogamy — where two people agree to be sexually exclusive with each other and have both been tested and confirmed to be STI-free before beginning an exclusive sexual relationship — is one of the most effective prevention strategies available. However, it must be emphasized that both partners need to have current, accurate STI testing results, not simply an assumption of exclusivity or a self-reported clean history, for monogamy to function as reliable prevention.
Barrier Methods: Condoms and Beyond
Condoms are the single most widely available and effective tool for STI prevention during sexual activity. Used consistently and correctly, male condoms reduce the risk of transmission for HIV, gonorrhea, chlamydia, and other infections transmitted through bodily fluids by approximately 80 to 95 percent. They also provide meaningful, though less complete, protection against infections transmitted through skin-to-skin contact, such as herpes and HPV, by covering the areas most likely to be involved in transmission.
The critical word is "consistently." Many studies show that the benefit of condoms in practice is considerably less than under ideal conditions because condoms are frequently not used consistently for every act of intercourse or not used correctly. Common errors include not leaving space at the tip of the condom, not rolling it down fully, using oil-based lubricants with latex condoms (which can degrade the latex), and putting the condom on partway through intercourse rather than at the beginning. Education about proper condom use is therefore a critical component of STI prevention education.
External condoms, commonly called male condoms, are the most familiar form. They are made primarily from latex, though polyurethane and polyisoprene options are available for people with latex allergies. Lambskin or natural membrane condoms, while effective at preventing pregnancy, do not provide reliable protection against STIs because they have pores that allow viruses to pass through.
Internal condoms, commonly called female condoms, are worn inside the vagina or anus and provide similar protection to external condoms while offering the advantage of being able to be inserted before sexual activity begins. They also give people with vaginas more agency over their own protection. Internal condoms are made of nitrile, which is suitable for people with latex allergies, and can be used with oil-based or water-based lubricants.
Dental dams — thin sheets of latex or polyurethane — can be used as a barrier during oral-vaginal or oral-anal contact. They are less widely known and less commonly used than condoms, but they provide meaningful protection during these activities which, while generally lower risk than penetrative intercourse, can still transmit certain STIs including herpes, gonorrhea, and HPV. Dental dams can be purchased commercially or made from a condom by cutting it open.
Lubrication as a Prevention Tool
While not itself a barrier method, the use of appropriate lubrication plays an important supportive role in STI prevention. Adequate lubrication reduces friction during sexual activity, which reduces the risk of microscopic tears in the skin and mucous membranes that can serve as entry points for pathogens. For anal sex in particular, where natural lubrication is absent and the rectal tissue is particularly vulnerable to tearing, generous lubrication is especially important.
Water-based and silicone-based lubricants are safe to use with latex condoms. Oil-based lubricants, including petroleum jelly, coconut oil, and most lotions, can degrade latex condoms, making them more likely to break, and should be avoided for this purpose. Silicone-based lubricants, while safe with latex condoms, can damage silicone sex toys.
Chapter Four: Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis, and Antiviral Prevention
PrEP: A Revolution in HIV Prevention
One of the most transformative developments in HIV prevention in recent decades has been the development and widespread availability of pre-exposure prophylaxis, commonly known as PrEP. PrEP involves taking antiretroviral medication daily (or in some formulations, on a schedule around sexual activity) to prevent HIV infection in people who are HIV-negative but at substantial risk of exposure.
The original PrEP medication, a combination pill containing tenofovir disoproxil fumarate and emtricitabine marketed as Truvada, was approved by the FDA in 2012. When taken as prescribed, daily oral PrEP reduces the risk of sexually acquired HIV by more than 99 percent. A newer combination, tenofovir alafenamide and emtricitabine marketed as Descovy, was approved in 2019 with a similar efficacy profile and a somewhat better safety profile for kidney and bone health.
More recently, an injectable form of PrEP using the long-acting antiretroviral cabotegravir, marketed as Apretude, was approved by the FDA in 2021. This injectable PrEP is administered by a healthcare provider once every two months and has been shown in clinical trials to be even more effective than daily oral PrEP, largely because it eliminates the challenge of daily adherence. For many people, particularly those who find it difficult to take a pill every day without missing doses, injectable PrEP represents a significant advance.
PrEP is recommended for adults who are HIV-negative and at substantial risk of HIV, including gay and bisexual men who have had anal sex without a condom or been diagnosed with an STI in the past six months, heterosexual men and women whose partners are HIV-positive or who do not consistently use condoms, and people who inject drugs and share equipment. PrEP requires a prescription, regular HIV testing (typically every three months), monitoring of kidney function, and ongoing care from a healthcare provider.
It is important to note that PrEP prevents only HIV and does not protect against other STIs. People on PrEP should continue to use condoms for protection against other infections.
PEP: Emergency HIV Prevention
Post-exposure prophylaxis, or PEP, is an emergency HIV prevention measure involving a course of antiretroviral medications taken after a potential HIV exposure. PEP must be started within 72 hours of a potential exposure and is taken daily for 28 days. The sooner it is started after an exposure, the more effective it is; ideally it should be initiated within 24 hours.
PEP is intended for emergency situations, not as a routine prevention strategy. Situations in which PEP should be considered include unprotected sex with a partner of unknown or HIV-positive status where a condom was not used or broke, sexual assault, and needlestick injuries in healthcare settings. Anyone who thinks they may have been exposed to HIV should contact a healthcare provider, emergency room, or urgent care clinic immediately to discuss whether PEP is appropriate.
PEP is highly effective when started promptly and taken as prescribed, but it is not 100 percent effective, and there can be side effects including nausea and fatigue. It should always be followed by a discussion with a healthcare provider about ongoing HIV prevention strategies including PrEP if the individual is at ongoing risk.
Antivirals for Herpes Prevention
For people living with genital herpes who have regular sexual partners, daily antiviral suppressive therapy with medications like valacyclovir can significantly reduce the frequency of outbreaks and, importantly, the risk of transmitting the virus to partners. Studies have shown that daily suppressive therapy reduces the risk of herpes transmission by approximately 48 percent in heterosexual couples, in combination with condom use which provides additional protection.
This represents an important prevention option that is not always adequately discussed. For people in serodiscordant relationships — where one partner has herpes and the other does not — a combination of daily suppressive antivirals, consistent condom use, and avoiding sexual contact during and immediately around outbreaks represents the most comprehensive risk reduction approach.
Treatment as Prevention for HIV
The concept of treatment as prevention for HIV reflects the scientific understanding that people living with HIV who are on effective antiretroviral therapy and maintain an undetectable viral load in their blood cannot transmit the virus to sexual partners. This is the foundation of the U=U campaign mentioned earlier. Large-scale clinical trials including the PARTNER study and HPTN 052 have provided robust evidence that undetectable equals untransmittable.
This has profound implications for both prevention and destigmatization. It means that a person living with HIV who is engaged in care and virally suppressed poses no risk of sexual HIV transmission. Knowing one's status, accessing treatment, and staying in care is therefore both a matter of personal health and a powerful prevention strategy for partners.
Chapter Five: Vaccination — Preventing STIs Before Exposure
The HPV Vaccine
The development of vaccines against human papillomavirus represents one of the most significant achievements in cancer prevention in history. Currently available HPV vaccines protect against the strains of HPV most commonly associated with cervical cancer and genital warts. The nine-valent HPV vaccine, Gardasil 9, protects against nine HPV strains, including the two highest-risk strains responsible for approximately 70 percent of cervical cancers and two low-risk strains responsible for approximately 90 percent of genital warts.
HPV vaccination is most effective when given before any sexual activity begins, before exposure to the virus. In the United States, the vaccine is recommended for all adolescents at age 11 or 12 years, with catch-up vaccination recommended for everyone through age 26 who was not previously vaccinated. Adults between 27 and 45 may also benefit from vaccination in some circumstances, and should discuss this with their healthcare provider.
The HPV vaccine is given as a series of shots — two shots for those who receive it before age 15, and three shots for those who start the series at 15 or older or who are immunocompromised. It is extremely safe; the most common side effects are soreness at the injection site and temporary dizziness.
The evidence for the vaccine's effectiveness is compelling. Countries with high HPV vaccination rates have seen dramatic reductions in HPV infections, genital warts, and precancerous cervical lesions in vaccinated populations. Australia, which introduced a comprehensive school-based HPV vaccination program in 2007, is on track to become the first country in the world to eliminate cervical cancer as a public health problem.
The Hepatitis B Vaccine
Hepatitis B vaccination is one of the most effective public health interventions available. The hepatitis B vaccine, a series of typically three shots given over six months, provides long-lasting protection against hepatitis B infection in more than 90 percent of adults. Vaccination is recommended for all infants beginning at birth, for children and adolescents who have not previously been vaccinated, and for adults who are at risk of hepatitis B infection, including all adults under 59 regardless of risk factors and adults over 60 who wish to be protected.
Universal hepatitis B vaccination programs in many countries have dramatically reduced the incidence of acute hepatitis B infection and the long-term liver disease and cancer that results from chronic infection. Countries like Taiwan that implemented universal newborn vaccination programs decades ago have seen dramatic reductions in childhood liver cancer rates as a direct result.
The Hepatitis A Vaccine
While hepatitis A is not exclusively an STI, it can be transmitted through certain sexual practices including oral-anal contact, and is therefore an important consideration in sexual health vaccination. Hepatitis A vaccination is recommended for all children at one year of age, for travelers to certain countries, and for adults who are at increased risk, including men who have sex with men. The hepatitis A vaccine is given as a two-shot series and provides long-lasting protection.
Emerging Vaccine Developments
Research into vaccines for other STIs is ongoing. An HIV vaccine remains one of the holy grails of infectious disease research, but despite decades of effort, the extraordinary genetic variability of HIV and the complexity of the immune responses needed to prevent infection have made vaccine development exceptionally challenging. Several candidate vaccines have entered clinical trials, and novel approaches including mRNA technology are being explored.
Research into herpes vaccines has also been ongoing for decades without yet producing an approved product, though several promising candidates are in development. A vaccine for gonorrhea is being studied, building on the observation that people previously vaccinated against the closely related meningococcal bacterium appear to have some cross-protection against gonorrhea. The development of new vaccines against STIs remains a critical area of global health research.
Chapter Six: Regular Testing — The Cornerstone of STI Prevention and Control
Why Testing Is Prevention
Regular STI testing is not simply a response to a problem — it is itself a form of prevention. This distinction is crucial and often misunderstood. Because so many STIs cause no symptoms, particularly in their early stages, the only way to know one's status with confidence is through testing. Knowing one's status allows individuals to access treatment if infected, notify partners so they can also be tested, and make more informed decisions about prevention strategies going forward.
From a public health perspective, widespread testing is essential for breaking chains of transmission. If a significant proportion of STI infections go undetected and untreated, those infected individuals continue to unknowingly transmit infections to partners, who then transmit to their partners, and so on. Early detection and treatment interrupts this cycle.
How Often Should You Get Tested?
The frequency of STI testing that is appropriate for any individual depends on their specific circumstances, including their sexual practices, the number of partners they have, whether they use condoms consistently, and other risk factors. General guidelines from major public health bodies offer a starting framework.
For sexually active individuals, annual testing for HIV, syphilis, gonorrhea, and chlamydia is a reasonable minimum baseline. The CDC recommends that sexually active women under 25 get tested for chlamydia and gonorrhea every year. Women 25 and older should be tested if they have new or multiple partners or their partner has other partners. For men who have sex with men, the recommendations are more frequent: HIV testing every three to six months, and testing for gonorrhea, chlamydia, and syphilis at least annually and more frequently if having sex without condoms or with multiple partners.
For people on PrEP, HIV testing is required every three months as part of the PrEP protocol. People with new sexual partners are advised to test before and after changing partners, and ideally both partners should test together before discontinuing condom use.
Cervical cancer screening through Pap smears and HPV testing is a distinct but related aspect of sexual health monitoring. Current guidelines in the United States recommend that women begin cervical cancer screening at age 21 and continue every three years with Pap smears alone or every five years with combined Pap and HPV testing from age 30 onward.
Where to Get Tested
There are now more options than ever for STI testing, which has helped address some of the access barriers that previously prevented many people from knowing their status. Options include primary care physicians and family medicine practices, sexual health clinics and STI clinics, Planned Parenthood and similar reproductive health organizations, community health centers, urgent care clinics, and a growing number of at-home testing services.
At-home STI testing kits have become increasingly sophisticated and widely available, allowing people to collect samples at home and mail them to a laboratory. Results are typically delivered through a secure online portal or app. While at-home testing has dramatically expanded access and addressed some of the stigma associated with in-person testing, it works best within a framework that includes linkage to care if results are positive.
Partner Notification
When someone tests positive for an STI, notifying sexual partners so they can also be tested and treated is one of the most important steps in interrupting transmission chains. Partner notification can be one of the most emotionally challenging aspects of dealing with an STI diagnosis, but it is also one of the most socially responsible.
Most public health departments offer partner notification assistance services, sometimes called disease intervention services, where public health professionals can help notify partners confidentially without disclosing who the index case is. Many sexual health clinics also offer partner notification support. Digital partner notification services have emerged in recent years, allowing people to send anonymous text messages or emails to partners informing them that they may have been exposed to an STI and should get tested.
Chapter Seven: Communication, Consent, and Sexual Health Conversations
The Challenge and Importance of Talking About Sexual Health
For all the advances in medical technology, vaccines, and testing, one of the most fundamental — and often most difficult — aspects of STI prevention comes down to human communication. Talking openly and honestly with sexual partners about sexual health, STI status, testing history, and prevention preferences is essential for informed consent and effective prevention, yet it remains one of the areas where many people feel least equipped and most uncomfortable.
The discomfort around sexual health conversations is deeply rooted in cultural and social norms that have long treated sex as a taboo subject, something private and not to be discussed openly. Stigma around STIs adds another layer of difficulty. Many people fear that disclosing an STI status or asking a partner about theirs will be met with rejection, judgment, or negative assumptions about their sexual history or character. These fears, while understandable given the cultural context, ultimately serve to impede the honest communication that is essential for prevention.
Developing the capacity for open, honest, and non-judgmental conversations about sexual health is a skill, and like any skill it can be learned and practiced. The more normalized these conversations become, the easier they become for everyone.
How to Have the Conversation
There is no single perfect way to discuss sexual health with a partner, but certain principles can make these conversations easier and more productive. Timing and setting matter: raising the topic when both people are relaxed, sober, and not in the middle of sexual activity allows for a more measured and thoughtful conversation. Choosing a neutral setting where both people feel comfortable and private helps create the conditions for honest dialogue.
Starting with one's own status and testing history can lower the defensive temperature of the conversation. Saying "I was tested six months ago and everything was clear, but I'm due for testing again" invites reciprocal disclosure in a much less confrontational way than leading with demands or accusations. Using "I" statements and expressing personal values around sexual health as a form of self-care rather than as an interrogation of the other person's past tends to be more effective.
It is also important to be prepared for different responses. Not everyone will respond with immediate openness and full disclosure, particularly if they have not recently been tested or are uncertain of their status. A partner who is defensive or dismissive about sexual health conversations is, itself, important information for making decisions about the relationship.
Consent and Its Relationship to STI Prevention
Consent — the ongoing, informed, enthusiastic agreement to engage in sexual activity — and STI prevention are closely intertwined. Truly informed consent includes accurate information about each person's STI status. A person who knowingly has an STI and does not disclose this to a partner before sexual activity without taking protective measures is violating their partner's ability to make a fully informed decision.
Many jurisdictions have laws requiring disclosure of certain STI statuses, particularly HIV, before engaging in sexual activity. While the legal landscape around STI disclosure is complex and varies considerably by location, the ethical principle is clear: partners have a right to information that is material to their health and safety when making decisions about sexual activity.
It is also important to note that consent applies to the use of prevention methods. A partner who agrees to use a condom and then secretly removes or damages it — a practice known as stealthing — is committing a serious violation of consent. Agreements around prevention methods are part of the broader consent framework for sexual activity.
Navigating Disclosure of STI Status
For people living with a chronic STI — herpes, HIV, HPV, or others — disclosure to sexual partners is a recurring challenge that carries significant emotional weight. The fear of rejection, the anticipation of stigma, and the vulnerability of sharing personal health information all make disclosure genuinely difficult.
However, disclosure, combined with clear communication about risk reduction strategies, typically goes better than anticipated. Many people are more accepting and understanding than feared, particularly when the person disclosing is calm, knowledgeable, and prepared to answer questions and discuss prevention. Practicing what one wants to say beforehand, perhaps with a trusted friend, therapist, or healthcare provider, can help build confidence.
Resources for people navigating disclosure decisions include sexual health organizations, support groups for people with specific STIs, and therapists with experience in sexual health. Online communities also provide spaces for people to share experiences and advice around disclosure.
Chapter Eight: Special Populations and Contexts
Sexual Health for Young People
Young people between the ages of 15 and 24 face disproportionate rates of STIs in virtually every country where data is collected. Multiple factors contribute to this: the biological susceptibility of younger women's cervical tissue to infection, the tendency for sexual networks to be more closely connected among younger people, less experience with and confidence in navigating prevention conversations, potentially lower consistent condom use, and in many cases limited access to confidential sexual health care.
Comprehensive sex education that is medically accurate, age-appropriate, and inclusive has been shown to reduce STI rates and unintended pregnancies while not increasing rates of sexual activity — contrary to the concerns sometimes raised about education in this area. Young people who receive comprehensive sex education are more likely to delay sexual debut, use condoms consistently when they do become sexually active, and access healthcare appropriately.
Ensuring that healthcare for young people is confidential is critically important. Many young people avoid seeking sexual health care because they fear their parents will be informed. While laws on confidentiality for minors' sexual health care vary by jurisdiction, many places do allow minors to receive STI testing and treatment confidentially. Healthcare providers and health systems should make their confidentiality policies clear and should create environments where young people feel safe seeking care.
Sexual Health for LGBTQ+ Individuals
LGBTQ+ individuals face both unique sexual health considerations and significant barriers to care. Gay and bisexual men and other men who have sex with men face higher rates of HIV, gonorrhea, syphilis, and certain other infections due to the higher background prevalence of these infections in their sexual networks and the greater transmission efficiency of certain acts. Comprehensive, targeted prevention messaging, access to PrEP, and regular testing are particularly important for this population.
Transgender and gender non-conforming individuals face significant healthcare barriers including providers who lack knowledge about their specific health needs, environments that are not inclusive or welcoming, and the complex interplay between gender-affirming healthcare and sexual health. Healthcare providers should be trained in trans-inclusive sexual health care, and prevention resources should be explicitly inclusive of transgender people.
Lesbian and bisexual women have often been told they are at low risk for STIs, which has led to under-testing and under-treatment. In reality, STIs including herpes, trichomoniasis, bacterial vaginosis, and HPV can all be transmitted between women through sexual contact involving shared fluids or skin contact. Sexual health care for women who have sex with women should be just as thorough as for other populations.
Sexual Health During Pregnancy
STI prevention and screening during pregnancy is critically important because many STIs can have severe consequences for the developing baby. Syphilis can cause congenital syphilis, leading to stillbirth, serious birth defects, and life-threatening illness in the newborn. Untreated gonorrhea and chlamydia can cause eye infections in the newborn during passage through the birth canal, potentially leading to blindness if not treated. HIV can be transmitted from mother to baby during pregnancy, childbirth, or breastfeeding, though with appropriate antiretroviral treatment the risk can be reduced to less than one percent. Herpes can cause neonatal herpes, which is rare but can be severe if the baby is exposed to active sores during delivery.
Standard prenatal care in most countries includes STI screening, typically including testing for syphilis, gonorrhea, chlamydia, hepatitis B, and HIV. Women at higher risk may need more frequent testing throughout pregnancy. Women diagnosed with STIs during pregnancy should receive prompt treatment, both for their own health and to protect the baby.
Aging and Sexual Health
Sexual health does not end at a certain age, but older adults are often overlooked in STI prevention education and campaigns, leading to significant under-testing and rising STI rates in this demographic. STI rates among adults over 50 have been rising in recent years in the United States and other countries. Several factors contribute to this trend: more older adults are sexually active than previously assumed, many older adults date again after divorce or the death of a spouse without updating their knowledge of STI prevention, and older adults may assume they are not at risk for STIs and therefore forgo condoms or testing.
Healthcare providers should routinely discuss sexual health with older patients and should not make assumptions about their level of sexual activity. Older adults should be aware that they are not immune to STIs and should apply the same prevention strategies as younger adults.
Chapter Nine: The Role of Structural Factors and Public Health
Stigma as a Barrier to Prevention
Stigma surrounding STIs is one of the most significant and destructive barriers to effective prevention and control. STI stigma operates at multiple levels: internalized stigma (the shame and self-blame that individuals feel when diagnosed), interpersonal stigma (judgment and rejection from partners, friends, and family), and structural stigma (institutional barriers and discrimination within healthcare systems and beyond).
The consequences of STI stigma are profound and largely counterproductive to public health goals. Stigma prevents people from getting tested because they fear what a positive result would mean for their social identity and relationships. It prevents people from disclosing to partners. It drives people away from healthcare settings where they experience judgment. It prevents open public conversation that could normalize prevention behaviors.
Reducing STI stigma requires multi-level intervention. At the individual level, it requires challenging the narrative that STIs are markers of moral failure or promiscuity and replacing it with an understanding of STIs as health conditions that can affect anyone who is sexually active. At the interpersonal level, it requires building cultures of non-judgmental conversation about sexual health. At the structural level, it requires healthcare training that ensures providers deliver sexual health care without judgment, and public health messaging that destigmatizes testing and treatment.
Healthcare Access and Equity
Access to sexual health care is profoundly unequal, and these inequalities track closely with existing disparities in race, income, insurance status, and geographic location. Communities of color, rural communities, low-income communities, and communities without health insurance face significant barriers to accessing the testing, treatment, and preventive services that are foundational to STI prevention.
Public health infrastructure for STI prevention and control, including publicly funded sexual health clinics, has been significantly reduced in many parts of the United States and other countries through budget cuts in recent decades. The impact of these cuts falls disproportionately on the most vulnerable communities, contributing to the stark racial and geographic disparities in STI rates observed in epidemiological data.
Ensuring universal access to sexual health care, including STI testing and treatment, condoms, vaccines, and PrEP, is not merely a matter of individual fairness — it is an essential component of effective public health. STIs do not respect the boundaries between communities; allowing STI rates to remain high in any community ultimately affects the entire population.
Sex Education Policy
The quality and content of sex education in schools has a significant impact on STI rates at the population level. Comprehensive sex education programs that provide medically accurate information about STIs, contraception, consent, healthy relationships, and communication skills are associated with lower rates of STI and lower rates of unintended pregnancy. Abstinence-only or abstinence-until-marriage programs, which withhold information about contraception and condom use, have not been shown to be effective at delaying sexual debut or reducing STI rates, and may actually be harmful by leaving young people without the knowledge and skills they need to protect themselves when they do become sexually active.
Advocacy for evidence-based comprehensive sex education is therefore a crucial component of STI prevention at the population level. This advocacy must also ensure that sex education is inclusive of LGBTQ+ students, who are often left invisible in curricula that assume heterosexual experience, leading to critical gaps in their sexual health knowledge.
Chapter Ten: Mental Health, Relationships, and the Psychology of Sexual Health
The Emotional Impact of STI Diagnosis
Receiving a diagnosis of an STI can trigger a wide range of emotional responses including shock, shame, anger, fear, and grief. These emotional responses are understandable, but they are also often significantly more distressing than the medical reality of the condition warrants — a consequence of the powerful stigma that surrounds STIs. For chronic STIs like herpes or HIV, the psychological adjustment to living with the diagnosis can be a significant process.
Mental health support should be an integral component of STI care. Healthcare providers should be aware of the potential emotional impact of a positive STI diagnosis and should respond with compassion and provide appropriate counseling and resources. For people who struggle significantly with the psychological impact of an STI diagnosis, therapy with a mental health professional experienced in sexual health issues can be enormously helpful.
Support communities, both in-person and online, can also provide invaluable perspective and connection for people adjusting to an STI diagnosis. Organizations dedicated to specific conditions often offer hotlines, online communities, and resources for navigating life with an STI, including support around disclosure and relationships.
Substance Use and Sexual Risk
There is a well-documented association between alcohol and substance use and increased sexual risk-taking, including reduced condom use, sex with more partners, and engagement in sexual acts that carry higher transmission risk. Alcohol and many recreational drugs lower inhibitions and impair judgment, making it harder to follow through on prevention intentions that are held when sober.
This relationship between substance use and sexual risk is particularly relevant for certain populations and contexts. Understanding this relationship is not about abstaining from all alcohol or substances in all circumstances — it is about being aware of how altered states can affect decision-making and taking steps to protect oneself, such as making decisions about prevention methods before drinking rather than in the moment.
For people whose substance use is significantly affecting their sexual health and overall wellbeing, addressing substance use disorders through appropriate treatment is itself a form of STI prevention.
Building Healthy Sexual Relationships
Ultimately, STI prevention exists within the broader context of healthy sexual relationships. Relationships characterized by mutual respect, open communication, shared responsibility for health and wellbeing, and genuine care for each other's welfare naturally incorporate STI prevention as part of a larger ethic of care.
Building the capacity for healthy sexual relationships involves developing skills including communication about boundaries, preferences, and health concerns; the ability to discuss consent explicitly and naturally; mutual responsibility for contraception and STI prevention; and the courage to end or modify relationships that are not safe or healthy.
Sexual health education that focuses exclusively on disease prevention misses the opportunity to support the development of these broader relationship skills that are ultimately the most powerful force for sexual wellbeing.
Chapter Eleven: Emerging Issues and the Future of STI Prevention
Antibiotic Resistance
The growing threat of antibiotic resistance poses a potentially serious challenge to STI prevention and treatment, particularly for gonorrhea. As described earlier, gonorrhea has progressively developed resistance to every antibiotic class that has been used to treat it, and treatment failures with the current recommended dual-antibiotic regimen are increasingly being reported globally. The WHO has classified drug-resistant gonorrhea as a priority public health threat.
The pipeline for new antibiotics has been worryingly thin for decades due to the limited financial incentives for pharmaceutical development of antibiotics compared to other drug classes. Several promising new antibiotics for gonorrhea treatment are in development, but the race between resistance development and new treatment options remains a concern. Preventing transmission in the first place — through condoms and other methods — takes on additional urgency in this context.
Digital Health and STI Prevention
Technology is increasingly being harnessed for STI prevention in innovative ways. Dating and hookup apps are increasingly incorporating sexual health features, including the ability to add STI testing status to profiles, reminders to test, links to testing resources, and integration with partner notification services. These applications reach many sexually active people who might not otherwise engage with sexual health messaging.
Telehealth services have dramatically expanded access to sexual health care, allowing people to consult with healthcare providers, receive PrEP prescriptions, and access STI treatment remotely. At-home STI testing services continue to improve in their sophistication, convenience, and linkage to care. Artificial intelligence is being explored for applications in sexual health including risk assessment, personalized prevention recommendations, and prediction of STI outbreaks at the population level.
Long-Acting Prevention Technologies
The development of long-acting prevention technologies holds particular promise for populations where daily medication adherence is challenging. In addition to long-acting injectable PrEP, researchers are working on vaginal rings that slowly release antiretroviral drugs over months, long-acting injectable and implantable antiretroviral formulations, and combination products that address both HIV prevention and contraception simultaneously.
The monthly dapivirine vaginal ring, which provides modest but meaningful reduction in HIV risk in women, has been approved in several countries and is being introduced in sub-Saharan Africa, where women bear a disproportionate burden of new HIV infections. The development of female-initiated, coitally-independent prevention technologies is particularly important for women in relationships where negotiating condom use may be difficult.
Conclusion: Toward a Culture of Sexual Health and Wellness
The prevention of sexually transmitted infections is not merely a matter of individual behavior and medical technology. It is embedded in the broader cultural, social, and structural conditions that shape how people understand and navigate their sexual lives. Achieving meaningful progress in STI prevention requires addressing all of these levels simultaneously.
At the individual level, the most powerful thing any sexually active person can do for their sexual health is to be informed, to get tested regularly, to communicate openly with partners, to use condoms consistently, to take advantage of available vaccines and preventive medications, and to approach their sexual health with the same intentionality they bring to other aspects of their physical and mental wellbeing.
At the interpersonal level, the commitment to honest communication about sexual health, to genuine respect for partners' wellbeing, and to shared responsibility for prevention creates the relational conditions within which individual prevention strategies are most effective.
At the cultural level, the work of destigmatizing STIs and sexual health conversations — through education, media representation, advocacy, and simply modeling open, non-judgmental discussions about sexual health in our own communities — is essential for creating the social environment where prevention can flourish.
At the structural level, ensuring universal access to high-quality, non-judgmental sexual health care; funding comprehensive, evidence-based sex education; addressing the social determinants of health that drive disparities in STI rates; and supporting research into new prevention tools are the policy and institutional imperatives that no amount of individual effort can substitute for.
Sexual health is health. It is a domain of human experience that encompasses not just the prevention of disease but the cultivation of positive, respectful, pleasurable, and consensual sexual lives. When we approach sexual health with the seriousness, care, and openness it deserves — when we treat it as an integral part of overall wellness rather than a source of shame or embarrassment — we create the conditions for not just lower STI rates, but for human flourishing in one of the most intimate and important dimensions of life.
The tools for preventing STIs are available. The knowledge is there. What remains is the individual and collective will to use them — to have the conversations, to seek the testing, to use the protection, to access the vaccines and medications, and to advocate for the social and structural conditions that make prevention accessible for everyone. That is the work of sexual health, and it is work that serves not only our own wellbeing but that of every person we are connected to in the web of human intimacy.
This article is intended for educational and informational purposes and should not be considered a substitute for professional medical advice. If you have concerns about your sexual health, please consult a qualified healthcare provider.
